US In Vitro Diagnostics Market Insight
Published: 11 June 2026 | Report Format: Electronic (PDF)
The United States In Vitro Diagnostics (IVD) Market is expected to grow at a rate of 6.12% owing to the rising prevalence of chronic and infectious diseases, increasing demand for early and accurate disease detection, expanding adoption of molecular diagnostics and point-of-care testing, and continuous advancements in automation, genomics, and personalized medicine technologies. The market is further supported by increasing laboratory testing volumes and growing investments in precision healthcare.
United States In Vitro Diagnostics Market Insights Forecasts to 2035
- The United States In Vitro Diagnostics Market Size Was Estimated at USD 43.7 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 6.12% from 2025 to 2035.
- The United States In Vitro Diagnostics Market Size is Expected to Reach Around USD 79.0 Billion by 2035.
Notable Insights for the United States In Vitro Diagnostics Market
- Segmentation on the basis of Product Type indicates that Reagents & Test Kits segment holds the dominant position in the United States In Vitro Diagnostics Market in 2025 with a market share of nearly 69% due to their recurring usage across clinical laboratories, hospitals, and diagnostic centers.
- Segmentation on the basis of Technology indicates that Immunoassay Diagnostics segment holds the dominant position in 2025 with a market share of approximately 33.5%, supported by widespread use in infectious disease testing, oncology, endocrinology, and chronic disease monitoring.
- Infectious disease diagnostics continue to represent the largest application segment, driven by routine screening programs, disease surveillance initiatives, and increasing testing demand across healthcare systems.
- Increasing adoption of molecular diagnostics, AI-enabled laboratory automation, liquid biopsy technologies, and precision medicine platforms is expected to drive market growth, improving diagnostic accuracy by up to 35% and reducing laboratory turnaround times by up to 30%.
Download the eBook (ToC)
Why Buy This Report
- Provides an in-depth analysis of trends in molecular diagnostics, laboratory automation, precision medicine, and point-of-care testing influencing the United States IVD market.
- Delivers strategic insights regarding innovations in genomic testing, liquid biopsy technologies, AI-powered diagnostic systems, and next-generation sequencing platforms.
- Assists stakeholders in evaluating competitive positioning, regulatory developments, reimbursement trends, healthcare investments, and expansion opportunities within the diagnostic healthcare sector.
Competitive Analysis:
The report gives an idea about big companies in the United States In Vitro Diagnostics Market. These companies are known for their products, tech and how they compete. They look at things like how efficient their productsre what new charging tech they have how they price things and how they get their products to customers. Companies are putting money into making adapters with Gallium Nitride, USB-C chargers that can charge fast and power solutions that are good, for the environment. Recent developments include collaborations with smartphone manufacturers, expansion of fast-charging product lines, and advancements in ultra-compact adapter designs.
Top Companies in United States In Vitro Diagnostics Market
- Abbott Laboratories
- Roche Diagnostics (F. Hoffmann-La Roche Ltd.)
- Siemens Healthineers
- Danaher Corporation (Beckman Coulter)
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- QIAGEN N.V.
- bioMérieux
- Becton, Dickinson and Company (BD)
- QuidelOrtho Corporation
Recent Developments:
- In June 2026, Samsung Electronics invested USD 175 million in Element Biosciences to support commercialization of advanced sequencing platforms and next-generation diagnostic technologies, highlighting growing investment activity within the U.S. diagnostics ecosystem.
- The United States diagnostics sector continues to witness strong growth in molecular diagnostics, liquid biopsy testing, oncology screening, and automated laboratory solutions, supported by increasing healthcare digitization and precision medicine adoption.
Market Segmentation:
United States In Vitro Diagnostics Market, By Product Type
- Reagents & Test Kits
- Instruments & Analyzers
- Diagnostic Software
- Laboratory Services
United States In Vitro Diagnostics Market, By Technology
- Immunoassays
- Molecular Diagnostics
- Clinical Chemistry
- Hematology
- Microbiology
- Point-of-Care Diagnostics
- Next-Generation Sequencing Diagnostics
United States In Vitro Diagnostics Market, By Application
- Infectious Diseases
- Oncology Diagnostics
- Cardiology Diagnostics
- Diabetes Monitoring
- Genetic Testing
- Autoimmune Disease Diagnostics
- Neurology Diagnostics
United States In Vitro Diagnostics Market, By End User
- Hospitals & Clinics
- Clinical Laboratories
- Diagnostic Centers
- Academic & Research Institutes
- Home Healthcare & Self-Testing
Expert Views:
The United States In Vitro Diagnostics market is expected to maintain robust growth over the forecast period due to increasing healthcare demand for rapid, accurate, and personalized diagnostic solutions. The expansion of molecular diagnostics, liquid biopsy testing, companion diagnostics, and genomic medicine is transforming disease detection and patient management. Healthcare providers are increasingly adopting AI-powered laboratory automation, digital pathology, and advanced sequencing technologies to improve efficiency and clinical outcomes. Furthermore, growing demand for home-based testing, preventive healthcare, and precision medicine is creating new opportunities across the diagnostics value chain. Supported by continuous technological innovation and strong investment in healthcare infrastructure, the United States IVD market is projected to experience sustained expansion through 2035.
Author: Govind and Krishna By Spherical Insights and Consulting